Our data suggests that CDKs, particularly CDK2 and CDK9, are promising therapeutic targets in NB and our study offers the possibility for the rational use of CDK inhibitors like dinaciclib as a new approach for the treatment of NB patients. This evidence concerns the gene CDK9 and neuroblastoma.